Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03300830 · ClinicalTrials.gov registry record
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
A clinical trial of Human Immunodeficiency Virus and Castleman's Disease, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 280
- Enrollment target
- 1
- Study location
NCT03300830: Recruiting study of Human Immunodeficiency Virus and Castleman's Disease, sponsored by National Cancer Institute (NCI).
NCT03300830 is a study of Human Immunodeficiency Virus and Castleman's Disease that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 280 participants, above the 177-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03300830, a study of Human Immunodeficiency Virus and Castleman's Disease, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 280 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to cause disease. Some variants are known to cause or affect diseases like cancer. Researchers want to study genetic variants in people with cancer who also have an immunologic disease like HIV. Objective: To study the biology of cancer in order to improve ways to prevent, detect, and treat it. Eligibility: Adults at least 18 years old with certain cancers and/or immunodeficiencies Design: Participants will be screened with medical history, physical exam, and lab tests. Participants will give samples of one or more tissue type. They may give blood or urine samples. Researchers may get samples of tissue when participants have surgery or when the participants are on other protocols in the NCI. Participants may have a procedure to have tissue samples removed. Researchers may collect data from participant medical records. Researchers will compare the genes in a participant s cancer tissue to their normal tissue. They may use the tissue cells to grow new cells in a lab. Participants may be contacted about the results. The samples will be stored for future research. No personal data will be kept with them. ...
Primary Outcome
Molecular data from viral associated malignancies, malignancies occurring in the setting of HIV or other immunodeficiencies, and Castleman disease
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2037-06-25 |
What NCT03300830 shows while recruiting
NCT03300830 is an observational study that tracks outcomes without assigning an intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 177-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (58% higher).
The record links to 4 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 0 interventions.
NCT03300830 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03300830 about?
NCT03300830 is a clinical study titled "Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease". Background: A person s genome is the collection of all their genes. A gene instructs individual cells to make proteins. Proteins are involved in all of our body s chemical processes. Genome sequencing allows researchers to find variations in genes. Some of these are normal and are not known to caus...
What is the current status of trial NCT03300830?
This trial is currently recruiting. The enrollment target is 280 participants. The study started on 2017-12-20. Estimated completion is 2037-06-25.
What conditions does trial NCT03300830 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer.
Who is sponsoring clinical trial NCT03300830?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03300830 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03300830's enrollment target sits among peer trials
280 9th of 39 higher than 31 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
Baricitinib for Reduction of HIV - CNS
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
RECRUITING
-
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
RECRUITING
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI